Key result
Elevated NT-proBNP (≥3,856 pg/mL) and H-FABP (≥8.8 ng/mL) were associated with increased mortality (HR 5.15 and 3.25, respectively).
Why the study?
Does the measurement of H-FABP and hsCRP improve mortality prediction in patients with increased NT-proBNP levels?
Cohort (n=278)
Does the measurement of H-FABP and hsCRP improve mortality prediction in patients with increased NT-proBNP levels?
The combined measurement of H-FABP with NT-proBNP provides a highly reliable means of short-term mortality prediction for patients hospitalized with elevated NT-proBNP.
Answers are grounded in this paper and cite their sources.
May support combined biomarker risk stratification in elevated NT-proBNP; leaves open incremental predictive value and prospective validation.
BACKGROUND: Amino-terminal pro-B type natriuretic peptide (NT-proBNP) is a well-established prognostic factor in heart failure (HF). However, numerous causes may lead to elevations in NT-proBNP, and thus, an increased NT-proBNP level alone is not sufficient to predict outcome. The aim of this study was to evaluate the utility of two acute response markers, high sensitivity C-reactive protein (hsCRP) and heart-type fatty acid binding protein (H-FABP), in patients with an increased NT-proBNP level. METHODS: The 278 patients were classified into three groups by etiology: 1) acute coronary syndrome (ACS) (n=62), 2) non-ACS cardiac disease (n=156), and 3) infectious disease (n=60). Survival was determined on day 1, 7, 14, 21, 28, 60, 90, 120, and 150 after enrollment. RESULTS: H-FABP (P<0.001), NT-proBNP (P=0.006), hsCRP (P<0.001) levels, and survival (P<0.001) were significantly different in the three disease groups. Patients were divided into three classes by using receiver operating characteristic curves for NT-proBNP, H-FABP, and hsCRP. Patients with elevated NT-proBNP (≥3,856 pg/mL) and H-FABP (≥8.8 ng/mL) levels were associated with higher hazard ratio for mortality (5.15 in NT-proBNP and 3.25 in H-FABP). Area under the receiver operating characteristic curve analysis showed H-FABP was a better predictor of 60-day mortality than NT-proBNP. CONCLUSIONS: The combined measurement of H-FABP with NT-proBNP provides a highly reliable means of short-term mortality prediction for patients hospitalized for ACS, non-ACS cardiac disease, or infectious disease.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2016) conducted a cohort in Increased levels of NT-proBNP (n=278). Elevated NT-proBNP (≥3,856 pg/mL) and H-FABP (≥8.8 ng/mL) vs. Lower levels of NT-proBNP and H-FABP was evaluated on Mortality (HR 5.15). Elevated NT-proBNP (≥3,856 pg/mL) and H-FABP (≥8.8 ng/mL) were associated with increased mortality (HR 5.15 and 3.25, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: